Shares of MetLife (NYSE:MET) have received a consensus recommendation of “Hold” from the twenty-two research firms that are covering the firm, MarketBeat reports. Two analysts have rated the stock with a sell recommendation, ten have given a hold recommendation, eight have issued a buy recommendation and one has given a strong buy recommendation to the company. The average twelve-month target price among analysts that have updated their coverage on the stock in the last year is $57.23.
A number of research analysts recently commented on the stock. Bank of America assumed coverage on shares of MetLife in a report on Monday, March 26th. They issued a “neutral” rating and a $50.00 price target for the company. Atlantic Securities raised shares of MetLife from a “neutral” rating to an “overweight” rating in a report on Monday, March 26th. Zacks Investment Research downgraded shares of MetLife from a “hold” rating to a “sell” rating in a report on Tuesday, March 20th. Wells Fargo reaffirmed a “buy” rating and issued a $60.00 price target on shares of MetLife in a report on Friday, March 16th. Finally, ValuEngine raised shares of MetLife from a “buy” rating to a “strong-buy” rating in a report on Wednesday, March 7th.
Shares of NYSE:MET traded down $0.87 during trading on Monday, reaching $45.02. The company’s stock had a trading volume of 7,454,740 shares, compared to its average volume of 7,313,565. The company has a current ratio of 0.15, a quick ratio of 0.15 and a debt-to-equity ratio of 0.29. MetLife has a 12 month low of $43.38 and a 12 month high of $55.91. The company has a market cap of $47,571.55, a price-to-earnings ratio of 10.00, a PEG ratio of 0.75 and a beta of 1.24.
The company also recently disclosed a quarterly dividend, which was paid on Tuesday, March 13th. Investors of record on Monday, February 5th were given a $0.40 dividend. This represents a $1.60 dividend on an annualized basis and a yield of 3.55%. The ex-dividend date of this dividend was Friday, February 2nd. MetLife’s dividend payout ratio (DPR) is currently 35.56%.
A number of institutional investors have recently bought and sold shares of the stock. Cambridge Investment Research Advisors Inc. increased its position in shares of MetLife by 17.1% during the fourth quarter. Cambridge Investment Research Advisors Inc. now owns 72,131 shares of the financial services provider’s stock worth $3,647,000 after acquiring an additional 10,513 shares during the period. Wagner Wealth Management LLC purchased a new position in shares of MetLife during the fourth quarter worth approximately $126,000. Xact Kapitalforvaltning AB increased its position in shares of MetLife by 6.0% during the fourth quarter. Xact Kapitalforvaltning AB now owns 161,838 shares of the financial services provider’s stock worth $8,183,000 after acquiring an additional 9,128 shares during the period. Envestnet Asset Management Inc. increased its position in shares of MetLife by 30.3% during the fourth quarter. Envestnet Asset Management Inc. now owns 234,037 shares of the financial services provider’s stock worth $11,834,000 after acquiring an additional 54,367 shares during the period. Finally, CNB Bank purchased a new position in shares of MetLife during the fourth quarter worth approximately $338,000. 77.69% of the stock is currently owned by institutional investors.
MetLife Company Profile
MetLife, Inc, through its subsidiaries, engages in the insurance, annuities, employee benefits, and asset management businesses. It operates through five segments: U.S.; Asia; Latin America; Europe, the Middle East and Africa; and MetLife Holdings. The company offers life, dental, group short- and long-term disability, individual disability, accidental death and dismemberment, vision, and accident and health coverages, as well as prepaid legal plans; administrative services-only arrangements to employers; and stable value products, including general and separate account guaranteed interest contracts, and private floating rate funding agreements.
Receive News & Ratings for MetLife Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for MetLife and related companies with MarketBeat.com's FREE daily email newsletter.